ÂÜÀòÂÒÂ×

Alan Wahl has a wealth of experience in the biotechnology and pharmaceutical industry. Alan is currently the Chief Executive Officer at Abacus Bioscience Inc, a position they have held since February 2022. Prior to their current role, Alan was the Principal at Westwahl LLC from January 2016 to January 2023. Before that, they served as the VP Discovery at Ambrx Inc from 2013 to November 2015. Alan has also held leadership positions at AbbVie, Biogen Idec, Trubion Pharmaceuticals, Seattle Genetics, and Bristol-Myers Squibb, where they contributed to various aspects of oncology research and development.

Alan Wahl obtained an MS and PhD in Biochemistry/Biophysics from the University of Rochester School of Medicine and Dentistry, where they studied from 1981 to 1985. Alan then pursued further education as a Research Fellow in Experimental Oncology at Stanford University School of Medicine from 1985 to 1989. Additionally, they had an unspecified educational experience at the University of Rochester School of Medicine and Dentistry, the details of which are not provided.